Neuralstem’s Financial Loss Widened in Second Quarter

Rockville-based Neuralstem reported a net loss of $3.2 million in the second quarter of the year. The company is still awaiting FDA approval to start the first round of human clinical trials for an ALS treatment candidate.

Click here to read more.

Share this: